Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Gross Profit (2016 - 2025)

Mimedx (MDXG) has disclosed Gross Profit for 15 consecutive years, with $99.0 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 30.32% to $99.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $345.6 million through Dec 2025, up 19.67% year-over-year, with the annual reading at $345.6 million for FY2025, 19.67% up from the prior year.
  • Gross Profit hit $99.0 million in Q4 2025 for Mimedx, up from $95.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $99.0 million in Q4 2025 to a low of $43.7 million in Q4 2021.
  • Historically, Gross Profit has averaged $66.2 million across 5 years, with a median of $67.3 million in 2023.
  • Biggest five-year swings in Gross Profit: decreased 24.28% in 2021 and later surged 38.22% in 2025.
  • Year by year, Gross Profit stood at $43.7 million in 2021, then surged by 37.27% to $60.0 million in 2022, then rose by 21.64% to $73.0 million in 2023, then grew by 4.12% to $76.0 million in 2024, then surged by 30.32% to $99.0 million in 2025.
  • Business Quant data shows Gross Profit for MDXG at $99.0 million in Q4 2025, $95.0 million in Q3 2025, and $79.9 million in Q2 2025.